J1S-MC-JP04: A Randomized, Open-Label Phase 2 Study Evaluating Abemaciclib in Combination with Irinotecan and Temozolomide in Participants with Relapsed or Refractory Ewing’s Sarcoma

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506772-28-00

Acronym

J1S-MC-JP04

Enrollment

Registered

2024-03-04

Start date

2022-10-07

Completion date

2025-07-19

Last updated

2025-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ewings Sarcoma

Brief summary

Progression Free Survival as determined by blinded independent review committee using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1)

Interventions

DRUGVerzenios 50 mg film-coated tablets

DRUGTEMOZOLOMIDE

DRUGIRINOTECAN

DRUGAbemaciclib

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Progression Free Survival as determined by blinded independent review committee using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1)	—

Countries

France, Germany, Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026